SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-06-22
👔
Definium Therapeutics, Inc.
@DFTX_InsiderForm 4 Filing: Wiley Matthew T. Acquires (Grant) shares of $DFTX
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
Definium Therapeutics, Inc.
Ticker: $DFTX
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-06-22
Shares: 62,500
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Wiley Matthew T., holds the title of Chief Commercial Officer at Definium Therapeutics, Inc..
On 2026-06-22, the insider transacted 62,500 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Wiley Matthew T. (Chief Commercial Officer) was granted $0 of $DFTX
Post-Transaction Position: 177,500 shares
SEC Accession No: 0001193125-26-276881 (CIK: 1759703)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.